Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
The present invention relates to a composition for implantation in the subretinal space of an eye, the composition including amniotic membrane, which may be cryopreserved human amniotic membrane, and a plurality of retinal pigment epithelial (RPE) cells or RPE equivalent cells present at the amniotic membrane. The amniotic membrane may be intact, epithelially denuded, or otherwise treated. The invention includes the use of amniotic membrane for the culturing of RPE cells thereon, forming a surgical graft for replacement of Bruch's membrane as a substrate, and for the transplanting of RPE cells to the subretinal space. The composition does not elicit immunological reactions to alloantigens or to RPE specific autoantigens; and exerts anti-inflammatory, and angiogentic, and anti-scarring effects. The invention includes methods and kits for making or using composites including amniotic membrane and RPE cells. Also disclosed is a device for harvesting RPE cells.
1. A method for treating a retinal disease, comprising inserting in a subretinal space of a human patient in need thereof a composite comprising amniotic membrane and non-immortalized human retinal pigment epithelial cells or non-immortalized human retinal pigment epithelial equivalent cells on the membrane, wherein the number of non-immortalized human retinal pigment epithelial cells or non-immortalized human retinal pigment epithelial equivalent cells on the membrane is from about 16,000 to about 20,000 per 4 mm 2 of amniotic membrane.
2. The method of claim 1 , wherein the retinal disease that is treated is selected from the group consisting of retinal detachment, gyrate atrophy, choroideremia, and age-related macular degeneration.
3. The method of claim 1 , wherein the amniotic membrane is human amniotic membrane.
4. The method of claim 1 , wherein the retinal pigment epithelial cells comprise retinal pigment epithelial cells cultured on the amniotic membrane.
5. The method of claim 1 , wherein the composite further comprises a pharmaceutically active molecule.
6. The method of claim 5 , wherein the pharmaceutically active molecule is selected from the group consisting of growth factors, enzymes, and therapeutic drugs.
7. The method of claim 1 , wherein the amniotic membrane is epithelially denuded.
8. The method of claim 1 , wherein the amniotic membrane is intact amniotic membrane comprising a basement membrane and a stroma.
9. The method of claim 8 , wherein mesenchymal cells are added to at least one side of the stroma before insertion in a subretinal space of a patient.
10. The method of claim 9 , wherein the mesenchymal cells are fibroblasts.
11. The method of claim 1 , wherein the amniotic membrane is treated on at least one side with excimer laser ablation before insertion in a subretinal space of a patient.
12. The method of claim 11 , wherein the excimer laser ablation alters the thickness of the stromal side or basement membrane side of the amniotic membrane.
13. The method of claim 1 , wherein the retinal pigment epithelial equivalent cells comprise cells selected from the group consisting of iris pigment epithelial cells, retinal pigment epithelial cells differentiated from at least one adult or embryonal stem cell, cells derived from neural retinal cells, and cells derived from a ciliary body.
14. The method of claim 6 , wherein the pharmaceutically active molecule is a growth factor selected form the group consisting of retinal pigment epithelium-derived growth factor, transforming growth factor-beta, and interleukin-10.
15. The method of claim 1 wherein the composite is formed by:
(a) applying at least one retinal pigment epithelial cell or retinal pigment epithelial equivalent cell to an amniotic membrane; and
(b) culturing the retinal pigment epithelial cell or retinal pigment epithelial equivalent cell on the membrane under conditions suitable for growth for a period of time sufficient to produce a plurality of cultured cells.